Cargando…

P1298: THE IRAK-4 INHIBITOR EMAVUSERTIB (CA-4948) FOR THE TREATMENT OF PRIMARY CNS LYMPHOMA

Detalles Bibliográficos
Autores principales:	Von Roemeling, C., Iqbal, M., Doonan, B., Hoang-Minh, L., Klippel, K., Tun, H., Mitchell, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431264/ http://dx.doi.org/10.1097/01.HS9.0000848056.06353.f1

Ejemplares similares

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
por: Von Roemeling, Christina A., et al.
Publicado: (2023)

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
por: Parrondo, Ricardo D., et al.
Publicado: (2023)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
por: Guidetti, Francesca, et al.
Publicado: (2023)

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade
por: von Roemeling, Christina, et al.
Publicado: (2023)

1298. Population Pharmacokinetics of Ceftazidime-avibactam among Critically-ill Patients with and without Receipt of Continuous Renal Replacement Therapy
por: Kline, Ellen G, et al.
Publicado: (2020)

1298. Validation of Local Pseudomonas aeruginosa Risk Factors in Patients with Community-Onset Bacterial Pneumonia
por: Pizzuti, Morgan, et al.
Publicado: (2021)

Multiply Relapsed Secondary CNS Non-Germinal Center Diffuse Large B-Cell Lymphoma Successfully Treated with CNS-Centric Therapy
por: Fournier, Lyndsey L, et al.
Publicado: (2023)

P1122: A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA
por: Habringer, Stefan, et al.
Publicado: (2023)

IRAK-4 Inhibitors for Inflammation
por: Wang, Zhulun, et al.
Publicado: (2009)

Irak : cinco años después /
por: Rosas, María Cristina
Publicado: (2008)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
por: Bennett, Joshua, et al.
Publicado: (2022)

Outgrowing IRAK-4
por: Bashyam, Hema
Publicado: (2007)

IRAK signalling in cancer
por: Rhyasen, G W, et al.
Publicado: (2015)

P1247: GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES
por: Yusuf, I., et al.
Publicado: (2022)

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
por: Zamora, Ernesto José Cuenca, et al.
Publicado: (2023)

Primary CNS Lymphoma
por: Phillips, Elizabeth H., et al.
Publicado: (2014)

P1160: METHOTREXATE IN COMBINATION WITH IBRUTINIB, THIOTEPA, RITUXIMAB (R-MTO) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANT FOR PRIMARY CNS LYMPHOMA
por: Xing, LI-Jie, et al.
Publicado: (2023)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
por: Doorduijn, J., et al.
Publicado: (2022)

The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists
por: Vollmer, Stefan, et al.
Publicado: (2017)

A144 CHRONIC DSS LEADS TO ALTERED EXPRESSION OF IRAK4/TPL2 PATHWAYS IN UC-COLONIZED MICE
por: Hann, A, et al.
Publicado: (2022)

P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA
por: Roddie, C., et al.
Publicado: (2022)

P1171: CNS RELAPSE OF DIFFUSE LARGE B-CELL LYMPHOMA. CLINICAL PRESENTATION, OUTCOME AND ROLE OF UPFRONT PROPHYLAXIS: A 10-YEAR SINGLE CENTER EXPERIENCE.
por: Benevolo Savelli, Corrado, et al.
Publicado: (2023)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Association of microRNA-146a and their target gene IRAK-1 polymorphism with enthesitis related arthritis category of juvenile idiopathic arthritis
por: Singh, Sushma, et al.
Publicado: (2014)

Selective predisposition to bacterial infections in IRAK-4–deficient children: IRAK-4–dependent TLRs are otherwise redundant in protective immunity
por: Ku, Cheng-Lung, et al.
Publicado: (2007)

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
por: Calimeri, Teresa, et al.
Publicado: (2022)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

IRAK4 inhibition to shut down TLR signaling in autoimmunity and MyD88-dependent lymphomas
por: Küppers, Ralf
Publicado: (2015)

PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA
por: Soussain, C., et al.
Publicado: (2022)

Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review
por: Kuhlman, Justin J, et al.
Publicado: (2021)

The Alphaviral Capsid Protein Inhibits IRAK1-Dependent TLR Signaling
por: Landers, V. Douglas, et al.
Publicado: (2021)

Intravascular Lymphoma in the CNS: Options for Treatment
por: Nizamutdinov, Damir, et al.
Publicado: (2017)

An audit on the diagnosis of primary CNS lymphoma
por: Joe, Dorothy, et al.
Publicado: (2021)

Primary CNS Lymphoma Masquerading as Ventriculitis
por: Rohatgi, Shalesh, et al.
Publicado: (2022)

P1165: PRELIMINARY FINDINGS OF A PHASE Ⅱ STUDY OF CHEMO-FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH-DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
por: Zhang, Yan, et al.
Publicado: (2023)

P1156: IN THE ABSENCE OF SYMPTOMS OR CEREBROSPINAL FLUID INVOLVEMENT, MRI STAGING OF THE CENTRAL NERVOUS SYSTEM (CNS) IN PATIENTS WITH SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA RARELY DETECTS DISEASE
por: Juneja, Manu, et al.
Publicado: (2023)

Helical assembly in the MyD88:IRAK4:IRAK2 complex in TLR/IL-1R signaling
por: Lin, Su-Chang, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6cr014k7eetb3184vpuko03nd5